In 2008, we wondered if the financial bubble would burst as financial institutions deemed “too big to fail” teetered during a global economic crisis. Today, we watch the same thing happen to healthcare—particularly the 340B Drug Pricing Program. Originally designed to help poor patients access affordable healthcare, it has grown into a $66 billion program, largely benefiting healthcare providers. Observers worry that waste, fraud, and abuse run deep because the program lacks meaningful accountability or transparency standards, especially among hospitals. Patients are starting to ask the question: Is the 340B Program the Next ‘Too Big to Fail’?